AU614607B2 - Use of and agent for reducing side effects of tnf - Google Patents
Use of and agent for reducing side effects of tnf Download PDFInfo
- Publication number
- AU614607B2 AU614607B2 AU34064/89A AU3406489A AU614607B2 AU 614607 B2 AU614607 B2 AU 614607B2 AU 34064/89 A AU34064/89 A AU 34064/89A AU 3406489 A AU3406489 A AU 3406489A AU 614607 B2 AU614607 B2 AU 614607B2
- Authority
- AU
- Australia
- Prior art keywords
- tnf
- paf
- composition
- side effects
- antagonist
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000000694 effects Effects 0.000 title claims abstract description 13
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 102000018594 Tumour necrosis factor Human genes 0.000 claims description 5
- 108050007852 Tumour necrosis factor Proteins 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 239000005557 antagonist Substances 0.000 claims description 4
- SCSIRWUYQVAIRL-UHFFFAOYSA-N ac1miw90 Chemical compound C1=2CC(C(=O)N(CCC)CCC)CC=2SC(N2C(C)=NN=C2CN=2)=C1C=2C1=CC=CC=C1Cl SCSIRWUYQVAIRL-UHFFFAOYSA-N 0.000 claims description 3
- FWYVRZOREBYLCY-UHFFFAOYSA-N bepafant Chemical compound C1C=2SC=3N4C(C)=NN=C4CN=C(C=4C(=CC=CC=4)Cl)C=3C=2CC1C(=O)N1CCOCC1 FWYVRZOREBYLCY-UHFFFAOYSA-N 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract description 11
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 abstract description 9
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
- 239000013543 active substance Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 206010054094 Tumour necrosis Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000002226 simultaneous effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Paper (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3816169A DE3816169A1 (de) | 1988-05-11 | 1988-05-11 | Verwendung und mittel zur verminderung der nebenwirkungen von tnf |
| DE3816169 | 1988-05-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU3406489A AU3406489A (en) | 1989-11-16 |
| AU614607B2 true AU614607B2 (en) | 1991-09-05 |
Family
ID=6354207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU34064/89A Ceased AU614607B2 (en) | 1988-05-11 | 1989-05-05 | Use of and agent for reducing side effects of tnf |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0341558B1 (OSRAM) |
| JP (1) | JP2709139B2 (OSRAM) |
| KR (1) | KR900017592A (OSRAM) |
| AT (1) | ATE78695T1 (OSRAM) |
| AU (1) | AU614607B2 (OSRAM) |
| CA (1) | CA1336825C (OSRAM) |
| DE (2) | DE3816169A1 (OSRAM) |
| DK (1) | DK220789A (OSRAM) |
| ES (1) | ES2042864T3 (OSRAM) |
| GR (1) | GR3005387T3 (OSRAM) |
| HU (1) | HUT52381A (OSRAM) |
| IL (1) | IL90206A0 (OSRAM) |
| ZA (1) | ZA893259B (OSRAM) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3735525C2 (de) * | 1987-10-20 | 1997-02-20 | Korth Ruth Maria | Verfahren zur Bestimmung der Wirksamkeit von paf-Acether-Rezeptor-Antagonisten |
| GB8926611D0 (en) * | 1989-11-24 | 1990-01-17 | Xenova Ltd | Compound and its use |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01500905A (ja) * | 1986-10-16 | 1989-03-30 | プレジデント アンド フェロース オブ ハーバード カレッジ | 腫瘍壊死因子と抗炎症剤との組合せおよび悪性腫瘍性および非悪性腫瘍性疾患の処置方法 |
-
1988
- 1988-05-11 DE DE3816169A patent/DE3816169A1/de not_active Withdrawn
-
1989
- 1989-05-01 KR KR1019890005809A patent/KR900017592A/ko not_active Withdrawn
- 1989-05-03 DE DE8989107969T patent/DE58901920D1/de not_active Expired - Lifetime
- 1989-05-03 ZA ZA893259A patent/ZA893259B/xx unknown
- 1989-05-03 EP EP89107969A patent/EP0341558B1/de not_active Expired - Lifetime
- 1989-05-03 ES ES89107969T patent/ES2042864T3/es not_active Expired - Lifetime
- 1989-05-03 AT AT89107969T patent/ATE78695T1/de not_active IP Right Cessation
- 1989-05-04 CA CA000598696A patent/CA1336825C/en not_active Expired - Fee Related
- 1989-05-05 HU HU892180A patent/HUT52381A/hu unknown
- 1989-05-05 AU AU34064/89A patent/AU614607B2/en not_active Ceased
- 1989-05-05 IL IL90206A patent/IL90206A0/xx unknown
- 1989-05-05 DK DK220789A patent/DK220789A/da not_active Application Discontinuation
- 1989-05-06 JP JP1113985A patent/JP2709139B2/ja not_active Expired - Lifetime
-
1992
- 1992-08-06 GR GR920401724T patent/GR3005387T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0341558A2 (de) | 1989-11-15 |
| DE58901920D1 (de) | 1992-09-03 |
| GR3005387T3 (OSRAM) | 1993-05-24 |
| KR900017592A (ko) | 1990-12-19 |
| DK220789D0 (da) | 1989-05-05 |
| DE3816169A1 (de) | 1989-11-23 |
| DK220789A (da) | 1989-11-12 |
| JPH0276825A (ja) | 1990-03-16 |
| ES2042864T3 (es) | 1993-12-16 |
| EP0341558A3 (en) | 1990-05-09 |
| ATE78695T1 (de) | 1992-08-15 |
| CA1336825C (en) | 1995-08-29 |
| HUT52381A (en) | 1990-07-28 |
| AU3406489A (en) | 1989-11-16 |
| IL90206A0 (en) | 1989-12-15 |
| JP2709139B2 (ja) | 1998-02-04 |
| ZA893259B (en) | 1991-01-30 |
| EP0341558B1 (de) | 1992-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2318849T3 (es) | Composiciones farmaceuticas para el suministro controlado de receptores solubles. | |
| US4734279A (en) | Combination of immunoglobulins with therapeutic agents | |
| ES2197912T3 (es) | Utilizacion de anticuerpos anti-tnf en la preparacion de medicamentos para tratar enfermedades con porcentaje serico elevado de interleucina-6. | |
| JP2002509529A (ja) | Ｉｌ−１媒介疾患を処置するためにｉｌ−１インヒビターを使用する組合せ療法 | |
| WO1991013628A1 (en) | Pharmaceutical compositions | |
| AU4787996A (en) | Calcitonin salmon analogues, their preparation, medicinal useand use as analytical agents | |
| KR101563069B1 (ko) | 다형 교모세포종의 치료를 위한 마시텐탄 포함 조합물 | |
| US5550153A (en) | Method for treating heartworm-infected canines | |
| RU2002105485A (ru) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) | |
| AU614607B2 (en) | Use of and agent for reducing side effects of tnf | |
| Mease | Psoriatic arthritis: the role of TNF inhibition and the effect of its inhibition with etanercept | |
| CA2408797A1 (en) | Treatment of breast cancer | |
| US6623732B1 (en) | Pharmaceutical formulation for nasal administration | |
| AU715260B2 (en) | TNF receptor and steroid hormone in a combined therapy | |
| CA2386583A1 (en) | Novel combination for the treatment of sexual dysfunction | |
| JPH06340549A (ja) | ネコの呼吸器疾患治療剤とその治療剤を用いる治療方法 | |
| JP2770911B2 (ja) | 抗ウイルス医薬組成物 | |
| CA2368352A1 (en) | Method for treating neurodegeneration | |
| Schirger et al. | Prazosin—new Hypertensive Agent: A Double-Blind Crossover Study in the Treatment of Hypertension | |
| WO2021233966A1 (en) | Methods for the treatment of coronavirus infections | |
| US7012060B1 (en) | TNF receptor and steroid hormone in a combined therapy | |
| DE60316407T2 (de) | Tumornekrosefaktor in kombination mit interferon zur behandlung und/oder verhinderung einer demyelinisierenden krankheit | |
| CA2013443A1 (en) | Pharmaceutical compositions and their use in the treatment of parasitoses | |
| ES2239954T3 (es) | Terapia contra el melanoma. | |
| CA1332222C (en) | Pharmaceutical composition for preventing and treating diseases caused by primary immune deficiences |